SRPTSarepta Therapeutics, Inc.
Is it safe?
Elevated bankruptcy risk: a balance sheet under strain, heavy debt (CCC), and big price swings. Everything else is secondary until this clears.
Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -93% · now 28% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can SRPT take a bad year?
Sarepta Therapeutics, Inc. carries $59M of net debt as at Q2 2026, with no operating profit to service it.
Net debt · as at Q2 2026 · debt less the cash on hand, with no positive EBITDA to service it
- Altman Z-score
- -1.05
Altman Z-score · distress zone, below 1.8
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 88%
Annualised volatility · S&P 500 16% · about 5 times the market's own swing
Details›
- Total debtQ2 2026
- $848M
- Cash and short-term investments
- $788M
- Net debt
- $59M
- EBITDA, trailing twelve months
- −$126M
- Operating profit, trailing twelve months
- −$143M
- Debt / equity
- 0.56×
- Annualised volatilitytwo years of daily moves
- 88%
- Worst drawdown on file
- −93%
- Below its 52-week high
- 28%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
The balance sheet
What it owes against what it owns, and how close that comes to trouble.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.